Navigation Links
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Date:6/10/2009

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign prostatic hyperplasia (BPH), a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone. Sanofi-aventis U.S. LLC entered into a previously announced agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

As a result of this collaboration between sanofi-aventis U.S. and AEterna Zentaris, patients completing two years of therapy in the North American trial of cetrorelix, NCT00449150, will be eligible to continue with cetrorelix treatment, according to treatment regimen of the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study will be followed-up for safety, International Prostate Symptom Score (IPSS) and quality of life during the extended treatment, providing follow-up data on cetrorelix for up to 5 years.

Juergen Engel, Ph.D., President and CEO of AEterna Zentaris commented, "We have been pleased with the decision of patients and their physicians to continue into this extended period of open-label treatment follow-up, sponsored by our partner sanofi-aventis U.S. We are confident that patients and their physicians will continue into this extension, as the continuation rate of patients into the open-label part of the study remains at over 90% of those eligible to continue at week 52 and compares favorably with those reported by others.(1) We look forward to presenting the data from the double-blind portion of the study in the next quarter."

About the Phase 3 Program with Cetrorelix in BPH

Cetrorel
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
2. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
3. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
4. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
5. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
6. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
7. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
8. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
9. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
10. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... can be pretty expensive. Now a team led by ... open-source library of designs that will let scientists slash ... the syringe pump. , Syringe pumps are used to ... or mixing chemicals in a reaction. They can also ... Pearce and his team of Michigan Tech students published ...
(Date:9/18/2014)... September 18, 2014 Silicon-valley Electronic Data ... Digitaliza TXT , the latest addition to Clinovo’s ... Clinical Research Organization (CRO) Program, Clinovo further expands its ... days of ClinCapture training, we are now able to ... Ana Pulido. “We can also rely on Clinovo to ...
(Date:9/17/2014)... FRANCISCO , Sept. 17, 2014 ... receiving accelerated partial breast irradiation (APBI) via interstitial ... those with positive lymph nodes could be suitable ... Radiation Oncology (ASTRO) guidelines place these patients in ... abstract at the 2014 ASTRO meeting, Beaumont Health ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... Corporation,(Nasdaq: VOLC ) today announced that it will ... of fiscal 2007 on Tuesday, February 12., The ... financial,results and operating activities open to all interested parties ... Time), Tuesday, February,12, hosted by Scott Huennekens, president and ...
... Begin at ProHEALTH Facility by End of First Quarter, ... NBS ),which is pioneering the pre-disease collection, processing ... need, today announced,receipt of a provisional license for comprehensive ... from the New York State,Department of Health for the ...
... - Three New Board Members to Form Audit ... 5 /Xinhua-PRNewswire-FirstCall/ --,China Pharma Holdings, Inc. ("China Pharma") ... generic and brand,bio-pharmaceutical products in China, today announced ... Baowen Dong to its Board of Directors,forming the ...
Cached Biology Technology:Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2NeoStem Announces NY State License for Adult Stem Cell Collection 2NeoStem Announces NY State License for Adult Stem Cell Collection 3China Pharma Appoints Three Independent Non-Executive Directors 2China Pharma Appoints Three Independent Non-Executive Directors 3
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... care to reproductive technologies, the justice and well-being ... people to identify key issues, articulate their values ... the most defensible ways forward. But what are ... conversations?, The Hastings Center and the Presidential Commission ... up to publish a series of essays to ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2Why bioethics literacy matters 2Why bioethics literacy matters 3Mellon Foundation awards grant for major project in the humanities and sciences 2
... April 22, 2012) Researchers at Columbia University Medical ... the retention and release of the brain,s stem cells. ... neurologic development and could eventually lead to regenerative therapies ... collaborative effort of the laboratories of Drs. Anna Lasorella ...
... reductions in salt content and taxation on products containing salt ... each year from cardiovascular disease (CVD) by 2-3 per cent ... World Congress of Cardiology are the first findings from a ... year. The study set out to assess ...
... the Florida campus of The Scripps Research Institute has been ... Health to develop a range of new tests that could ... degenerative disorders of advancing age. Shuji Kishi, an assistant ... three-year study. The new tests will focus on diseases ...
Cached Biology News:'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3Tax on salt could reduce cardiovascular disease deaths by 3 percent 2Researcher awarded $1 million for stress-associated disease and aging research 2
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: